As a clinical stage company, we are conducting human clinical testing of our lead product candidate, INT230-6, in refractory solid tumor cancers.

We have interest in collaborating with academic groups, universities, governmental agencies, pharmaceutical, imaging or biotechnology companies and private research institutes. Specifically, we would like to test combinations of our novel drug with products that may be synergistic. Data reported by Intensity Therapeutics have shown INT230-6 is synergistic with checkpoint blocking antibodies including anti-CTLA-4 and anti-PD-1 compounds.

Current Partnerships:

Merck Collaboration

Intensity has partnered with Merck & Co. to evaluate the combination of INT230-6 and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced solid malignancies including pancreatic, bile duct, squamous cell and non-MSI high colon cancers.  See press release for more information.

On March 30, 2020 we announced successful completion of the safety lead-in portion of the IT-01 KEYNOTE A10 study arm (NCT03058289) that is testing the combination of INT230-6 and Keytruda®.

Bristol Myers Squibb Collaboration

Intensity Therapeutics and Bristol Myers Squibb Company (BMS) are evaluating the safety and efficacy of INT230-6 when dosed in combination with BMS’ Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) immune checkpoint inhibitor Yervoy® (ipilimumab) in patients with solid tumors.  See press release for more information.

National Institutes of Health; National Cancer Institute – Collaborative Research and Development Agreement (CRADA)

In 2014, Intensity Therapeutics was awarded a cooperative research and development agreement (CRADA) from the National Institute of Health’s National Cancer Institute (NCI) Vaccine Branch. The purpose of the grant was to study the efficacy and mechanism of action of Intensity’s in situ tumor killing and antigen creation products using in vivo models of cancer.  Intensity sponsored a portion of the research program.  The CRADA explored the processes by which Intensity’s products elicit immune responses against cancer.  Two peer-review publications resulted from the highly productive collaboration; one article was solely authored by Intensity and published in the International Journal of Molecular Sciences (June 2020) and another publications was jointly authored and appeared in the journal Oncolmmunology (July 2019).  These papers are available on our website from the Publications page